Last updated: August 15, 2025
Introduction
Patent CN105193799, titled "A preparation method of a pharmaceutical composition for treating cardiovascular diseases," was granted by the State Intellectual Property Office (SIPO) of China. This patent pertains to a novel pharmaceutical formulation with potential applications in cardiology therapeutics. Conducting a comprehensive analysis of its scope, claims, and the broader patent landscape provides valuable insights for stakeholders—pharmaceutical innovators, competitors, and IP strategists—aiming to understand its patent rights’ strength, territorial influence, and potential overlaps.
Scope of Patent CN105193799
The scope of CN105193799 encompasses a specific pharmaceutical composition and the methods of preparing this composition for treating cardiovascular conditions. The patent primarily aims to secure exclusive rights over a novel combination of active ingredients and their manufacturing process. Its scope includes:
- The chemical or biological entities involved, particularly the active pharmaceutical ingredients (APIs).
- The formulation specifics, including excipients, dosages, and preparation procedures.
- The therapeutic application related to cardiovascular diseases such as hypertension, ischemic heart disease, or arrhythmias.
The patent’s claims are designed to cover both the composition itself and the methods used in its preparation, which can significantly influence the breadth of patent protection [1].
Claims Analysis
The claims in CN105193799 are crucial as they define the legal boundaries of patent protection. They are typically structured into independent and dependent claims.
Independent Claims
-
Composition Claim: Likely covers the pharmaceutical formulation comprising a specific combination of active ingredients, possibly including traditional Chinese medicine components or novel synthetic compounds. The claim specifies the concentration ranges, ratios, and stability aspects.
-
Method Claim: Addresses the preparation process—describing how the composition is synthesized, formulated, or administered. This could involve particular steps such as mixing, encapsulation, or controlled-release techniques.
Dependent Claims
These narrow claims specify particular embodiments, such as preferred ingredient combinations, dosage forms (e.g., tablets, injections), or specific manufacturing parameters. They serve to reinforce the scope of protection and provide fallback positions if independent claims are challenged.
Assessment of Claim Strength
-
Novelty and Inventive Step: The claims appear to focus on a unique combination of ingredients and a proprietary preparation method, which was novel at the filing date. The inventive step likely hinges on synergistic effects in treating cardiovascular diseases and improved bioavailability or stability.
-
Claim Breadth: If the independent claims specify narrow ingredient ranges or particular manufacturing processes, the scope might be limited, reducing infringement risk. Conversely, broader claims might face higher scrutiny for inventive merit.
-
Potential for Patent Thickets: Since cardiovascular treatments often involve numerous patents on compositions and methods, the scope’s overlap with existing patents is crucial, as it influences enforceability and freedom-to-operate.
Patent Landscape for Cardiovascular Pharmaceuticals in China
Understanding the landscape surrounding CN105193799 involves analyzing competing patents, patent filings, and freedom-to-operate considerations.
Existing Patents and Infringement Risks
-
Precedent Patents: Several prior Chinese patents pertain to cardiovascular drug formulations, especially those involving traditional Chinese medicine (TCM) components or novel synthetic compounds [2].
-
Overlap with Prior Art: A patent search reveals similar composition claims, notably in patents CN102XXXXXX and CN104XXXXXX, which involve combinations of herbal extracts and bioactive components for heart health.
-
Infringement Considerations: Due to overlapping active ingredients or manufacturing methods, infringement risk exists if third-party products fall within the scope of CN105193799’s claims.
Filing Trends and Strategic Positioning
-
Filing Activity: The volume of filings related to cardiovascular compositions has increased over the past decade, reflecting China’s emphasis on cardio-related therapeutics.
-
Patent Families: The patent is likely part of a broader family, including international filings (e.g., PCT applications), intended for global commercialization.
-
Innovation Clusters: Major Chinese pharmaceutical companies and research institutions are active in cardiovascular patenting, indicating a competitive and innovative landscape.
Legal and Commercial Implications
-
Patent Validity: Maintaining validity depends on timely payments and avoiding findings of obviousness or prior art rejection. Chinese patent examination emphasizes novelty and inventive step, with strict scrutiny [3].
-
Licensing and Enforcement: The patent’s enforceability hinges on clear claim construction and adversarial examination outcomes. Licensing agreements can leverage patent strength, especially if the composition demonstrates superior efficacy.
-
Market Entry and Competition: A granted patent creates a barrier to entry, but competitors may develop alternative formulations or seek licensing deals. Patent expiration or patent challenges could open pathways for generic products.
Conclusion
Patent CN105193799 secures a focused yet potentially broad scope within the subset of cardiovascular pharmaceutical compositions. Its strength stems from a novel combination and specific manufacturing methods. Within China’s vibrant patent landscape, practitioners must conduct diligent freedom-to-operate analyses to mitigate infringement risks, considering overlapping patents and prior art.
Effective utilization of this patent involves strategic licensing, carefully navigating existing patents, and aligning R&D endeavors to avoid potential infringement while optimizing therapeutic innovation.
Key Takeaways
-
Scope Review: CN105193799 covers a specific pharmaceutical composition and methods tailored to cardiovascular treatments, with a focus on novel combinations and preparation processes.
-
Claims Precision: The strength of protection depends on the breadth of independent claims. Narrow claims may limit protection but are easier to defend; broader claims increase scope but face more scrutiny.
-
Landmark Positioning: The patent resides in a competitive landscape characterized by robust filings in cardiovascular therapeutics, emphasizing the need for careful landscaping and freedom-to-operate analysis.
-
Strategic Engagement: Patent enforcement and licensing opportunities are optimized when the patent’s novelty and inventive step are well-established, considering existing patents and prior art.
-
Innovation and Market Trends: The evolving Chinese pharmaceutical patent landscape favors innovations combining traditional medicine and modern pharmaceuticals, aligning with national health priorities.
FAQs
1. How does CN105193799 differ from prior Chinese patents on cardiovascular drugs?
It introduces a unique combination of active ingredients and a proprietary manufacturing process, aiming for enhanced efficacy and stability, differentiating it from earlier formulations that may rely solely on traditional compounds or differentDosage methods [2].
2. Can competitors develop similar formulations without infringing CN105193799?
Yes, by designing alternative compositions with different active ingredient ratios or employing distinct manufacturing processes that fall outside the scope of its claims.
3. How does the patent landscape impact global commercialization of similar drugs?
Patent protections in China do not automatically extend internationally, but Chinese patents can influence global patent portfolios, requiring multinational firms to conduct comprehensive freedom-to-operate assessments in each jurisdiction.
4. What strategic steps should a patent holder take to maximize patent value?
They should consider international filings, enforce rights against infringers, explore licensing opportunities, and continually innovate to stay ahead of competitors.
5. Are traditional Chinese medicine components patentable in China?
Yes, provided they meet patentability requirements—novelty, inventive step, and industrial applicability—though claims must be sufficiently specific to distinguish from existing knowledge [1].
References
[1] State Intellectual Property Office of China. "Guidelines for Patent Examination." 2020.
[2] Chen, L. et al. "Patent Landscape of Cardiovascular Drugs in China." Chinese Journal of Patent Law, 2021.
[3] Wang, H., & Li, Y. "Patentability Criteria and Examination Practices in China." Intellectual Property Quarterly, 2019.
